tiprankstipranks
Evolus reports Q4 EPS (23c), consensus (15c)
The Fly

Evolus reports Q4 EPS (23c), consensus (15c)

Reports Q4 revenue $43.6M, consensus $43.79M. "We are pleased to announce our fourth quarter and full year results for 2022 highlighted by strong market share gains in the U.S., the first phase of our expansion into the European market, and disciplined operating expense management," said David Moatazedi, President and Chief Executive Officer. "For the second year in a row, Jeuveau was the fastest-growing neurotoxin in the U.S. aesthetic market, crossing into a double-digit unit share position. We also completed enrollment in our Phase II "extra-strength" study of Jeuveau, leading to the presentation earlier this year of very encouraging interim data. That data showed an extra-strength formulation of Jeuveau(R) demonstrated effects lasting 26 weeks representing prolonged 6-month performance compared to 21 weeks in the control arms."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on EOLS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles